When a mass is found in the ovary or on the peritoneum, one of the first questions a care team separates out is whether it started in the ovary or traveled there from another organ. For someone who has been treated for breast cancer, or is being treated now, a gynecologic or peritoneal lesion is usually approached with both possibilities left open. Two operations can look identical from the outside — both laparoscopic, both under general anesthesia — and still differ in purpose and extent depending on which answer the tissue gives.
In primary ovarian cancer, removing as much visible tumor as possible (debulking surgery) is generally one axis of treatment, and the amount of disease left behind is known to relate to later outcomes. Surgery there is part of the treatment itself. In metastatic breast cancer that has reached the ovary or peritoneum, the center of gravity shifts to systemic therapy — chemotherapy, endocrine (hormonal) therapy, targeted agents — and surgery is more often considered for a limited purpose: obtaining tissue, or relieving symptoms such as ascites or bowel obstruction. That is exactly where the question "biopsy only, or biopsy plus tumor removal?" comes from.
Timing of the answer matters. A frozen section performed during surgery can return within 30 to 60 minutes and is good at flagging whether a lesion is malignant and roughly what it looks like, but it has limits in confirming the organ of origin. Sorting out origin usually relies on the final pathology report together with immunohistochemistry, comparing a panel of markers, and that typically takes one to two weeks. Invasive lobular carcinoma of the breast is relatively known for spreading toward the peritoneum and gynecologic organs, so it is kept in the differential; spread from the stomach or bowel to the ovary is common enough to carry its own name (Krukenberg tumor). In other words, more than one direction of spread stays on the table until pathology settles it.
How much tissue is taken also shapes what comes next. Hormone receptor (ER/PR) and HER2 status in a metastatic site can differ from the original breast tumor — receptor discordance — so retesting the metastasis is generally recommended, and genomic or germline BRCA testing may be discussed as well. A small sample can mean a second procedure later, so it helps to ask beforehand which tests are planned and whether enough tissue will be collected for them.
Before the operating room, a few things are worth settling. First, scenario planning: ask how the extent of surgery changes if the frozen section suggests a primary ovarian cancer versus a breast origin, who makes that call in the room and on what basis, and whether family will be contacted during anesthesia. Second, gather records on one page: the earlier breast pathology report (histologic type, ER/PR/HER2), dates of diagnosis and recurrence, recent imaging and image discs, and the trend in tumor markers. Third, write down symptoms — abdominal distension, ascites, bowel changes, pain, appetite and weight — since these feed into the timing and sequence of treatment. Fourth, compare hospital plans by total time, not by surgery date alone: the interval from tissue sampling to a definitive answer to the first systemic treatment is closer to what actually matters. Fifth, ask whether a multidisciplinary discussion between the breast and gynecologic oncology teams is available.
This article is general health information and does not replace medical care for an individual. The actual tests, extent of surgery, and order of treatment depend on stage, pathology, and overall condition, so please discuss decisions with your own medical team.